Amgen Reports Second Quarter 2021 Financial Results
The Pharma Data
AUGUST 3, 2021
Food and Drug Administration (FDA) approved LUMAKRAS for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. In May, the U.S. XmAb is a registered trademark of Xencor, Inc. Tax Petition.
Let's personalize your content